Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis

FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet